Nasdaq GlobeNewswire

DSM Sinochem Pharmaceuticals successfully launches Rosuvastatin finished dosage formulation in Western Europe

Del

Rijswijk, Netherlands, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Upon patent expiry at the end of December 2017, DSM Sinochem Pharmaceutical (DSP) has successfully launched its fully backward integrated, generic Rosuvastatin drug product in multiple Western European countries. The successful launch will be extended to additional countries prior to the end of January, among which is the Netherlands.

After being one of the first companies globally to receive a CEP in early 2016 for Rosuvastatin API, DSP again proves to be a frontrunner by being one of the first to launch Rosuvastatin drug products in Western Europe using its in-house produced API.

Statins are currently the most prescribed drug class globally for high cholesterol and cardiovascular diseases and are among the top selling drugs worldwide. Rosuvastatin is used for reducing high cholesterol and preventing cardiovascular disease, which is the number one cause of death worldwide.

Quality, Reliability and Sustainability

In line with its brand promise of Quality, Reliability and Sustainability, DSP's Rosuvastatin offers customers superior performance in all three areas. For its finished dosage formulations, DSP uses its own in-house manufactured API. This proprietary, backward integrated, process, which is protected by 10 patent families, involves a highly efficient enzymatic coupling step, and offers customers independence from third party intermediate suppliers. Additional advantages to its API include unrivalled product quality with an assay of >99% and large batch sizes of 200 kg. This further results in significantly reduced Quality Assurance and testing costs, the absence of hazardous residual chemicals and a 35% reduced carbon footprint related to production.

Expanding portfolio

With the successful launch of the Rosuvastatin finished dosage formulation, on top of the earlier successful launch of DSP's beta lactam drug products, and the upcoming launch of Atorvastatin in Europe by summer 2018, the company is quickly expanding its drug product portfolio. What sets DSP apart from competitors is its backward integration and full control of its supply chain.

CEO, Karl Rotthier: "I am proud that our company, together with our partners, is among the first worldwide to launch a generic Rosuvastatin finished dosage formulation in Western Europe upon patent expiration; after being one of the first to offer the Rosuvastatin API under CEP. This shows our dedication to excellence and our aspiration to continue to be an industry leader".

BU Director Drug Products, Lucas Wiarda: "As with every one of our products, Rosuvastatin delivers superior performance on quality, reliability and sustainability compared to the industry average. This is largely due to DSP's full control of its manufacturing process from start to finish. Building on our strong position in beta lactams, Rosuvastatin is an excellent addition to our drug products portfolio which we proudly offer to our customers."

Currently DSP holds an eCTD dossier for Rosuvastatin finished dosage formulations (5,10,20 & 40mg FCT) containing Zone II & IV stability data and a 36 month shelf life.

About DSM Sinochem Pharmaceuticals

DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.

Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.

For more information please visit www.dsm-sinochem.com or contact DSM Sinochem Pharmaceuticals Corporate Communications, Erin van Wijngaarden, Manager PR & Corporate Communications. E-Mail: communications@dsm-sinochem.com

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7ac00118-d5bc-405d-a32d-b02d5c584c11

Erin van Wijngaarden
DSM Sinochem Pharmaceuticals
communications@dsm-sinochem.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DSM Sinochem Pharmaceuticals via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

CORRECTION - Elite Petro & Gas broadens financial services and signs a deal with Tabarak Investment Capital Limited18.10.2018 23:35Pressemelding

DUBAI, United Arab Emirates, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Today the President of Elite Petro & Gas, Mr. George Matharu and the President of Tabarak Investment Capital Limited (Investment Bank), Dr. Mohamed Ahmadi announced a deal in which the two companies will use their combined resources to execute physical commodity trades, and provide banking and finance facilities for oil and gas transactions. The alliance between the two entities will also allow compliance related activities to be carried out from two major international hubs of London and Dubai. This increases the international presence of both companies. Additionally, Elite Petro & Gas (“EPG”) has recently formed relationships with the owners of a number of high profile European, South American and Chinese projects, which EPG and Tabarak can work on together. Tabarak Investment Capital Limited is a regulated investment bank by Dubai Financial Services Authority and incorporated in the Dubai International Financial Centre.

Partnership Between Zaiput Flow Technologies and ThalesNano Set to Improve Process Intensification18.10.2018 15:21Pressemelding

BUDAPEST, Hungary and WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zaiput Flow Technologies, a global leader in separation, and ThalesNano, the world leader in bench-top flow chemistry reactors, recently signed a distribution agreement and entered into a technology partnership that exploits the benefits of their combined technologies. Under the distribution Zaiput liquid-liquid phase separators and back pressure regulators are available via ThalesNano in Europe and a number of other countries on a non-exclusive basis, either separately or as part of a bundled offering with ThalesNano’s own microflow reactors. Within the framework of the technology partnership the companies will collaborate to promote adoption of the combined use of their technologies. “We are very excited to work with ThalesNano to offer better-integrated flow chemistry systems to our customers and streamline the work of both novice and experienced users in the flow chemistry space,” said Zaiput CEO, Dr. Andrea Ad

Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer18.10.2018 14:03Pressemelding

NEW YORK and CLEVELAND, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of João Siffert, M.D. as Head of Research and Development and Chief Medical Officer. As a result, former Chief Medical Officer Juan Ruiz, M.D., Ph.D. will assume the role of Head of European Medical Affairs. The Company also announced the appointment of Neena Patil, J.D. as General Counsel and Corporate Secretary. Both Dr. Siffert and Ms. Patil report to Chief Executive Officer, Carsten Thiel, Ph.D. “I am very pleased to welcome João and Neena to Abeona, and confident in their abilities to make important contributions to the future growth of our company,” said Dr. Thiel. “João has an ideal blend of clinical, scientific, and regulatory experience to reference as we look to advance our clinical and pre-clinical can

Meltwater and Dow Jones Announce Global Partnership to Provide Premium Content18.10.2018 14:00Pressemelding

SAN FRANCISCO and NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Meltwater, a global leader in media intelligence, today announces the launch of a partnership with Dow Jones, a global provider of news and business information, to provide premium licensed content from Dow Jones Factiva into the Meltwater Media Intelligence platform. This partnership will give Meltwater’s PR and communications clients the ability to monitor and analyze premium licensed content across thousands of Factiva news sources globally, including: The Wall Street Journal, America’s largest newspaper by paid circulation; Barron’s; MarketWatch; and Dow Jones Newswires. “Meltwater provides our clients with the most comprehensive content network globally, across news, social media and broadcast media. This new Dow Jones partnership will further strengthen our leadership position and allow our clients to access licensed content from some of the most highly-respected news outlets in the world. We’re excited about this part

Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting18.10.2018 13:30Pressemelding

EMBARGOED FOR DISTRIBUTION Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until the officially scheduled date and time of presentation, symposia or poster session. Data to be presented across the Alzheimer’s disease clinical development portfolio, including aducanumab, BAN2401 and elenbecestat CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) announced it will present data from its Alzheimer’s disease (AD) clinical development portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in Barcelona, Spain (October 24-27). The data being presented are part of Biogen’s ongoing research programs targeting possible causes of the disease through multiple modalities. “We are excited to engage with the scientific community at CTAD, to share learnings from our Alzheimer’s disease clinical research and to learn from the work of our colleagues around the world. We have hopes that our

SEMAFO Provides Notice of Third Quarter 2018 Results Release and Conference Call   18.10.2018 13:30Pressemelding

MONTREAL, Oct. 18, 2018 (GLOBE NEWSWIRE) -- SEMAFO (TSX, OMX: SMF) invites you to participate in a conference call on November 7, 2018 at 10:00 AM EST with senior management during which they will review the Corporation's third quarter 2018 financial and operational results. SEMAFO's financial statements and management's discussion and analysis for the third quarter 2018 will be released on November 6 after market hours and will be available in the “Investor Relations” section of the Corporation's website at www.semafo.com , and on the Canadian Securities Administrators' website at www.sedar.com . A live audio webcast of the conference call will be accessible for a period of 30 days through SEMAFO’s website at www.semafo.com . Tel. local & overseas: +1 (647) 788 4922 Tel. North America: 1 (877) 223 4471 Webcast: www.semafo.com Replay overseas: +1 (416) 621 4642 Replay N. America: 1 (800) 585 8367 Replay pass code: 2823689 Expiration: December 7, 2018 About SEMAFO SEMAFO is a Canadian-b

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom